WO2022234593A1 - Compositions sublinguales comprenant nintedanib ou un sel de celui-ci - Google Patents

Compositions sublinguales comprenant nintedanib ou un sel de celui-ci Download PDF

Info

Publication number
WO2022234593A1
WO2022234593A1 PCT/IN2022/050414 IN2022050414W WO2022234593A1 WO 2022234593 A1 WO2022234593 A1 WO 2022234593A1 IN 2022050414 W IN2022050414 W IN 2022050414W WO 2022234593 A1 WO2022234593 A1 WO 2022234593A1
Authority
WO
WIPO (PCT)
Prior art keywords
sublingual
acid
nintedanib
composition
agent
Prior art date
Application number
PCT/IN2022/050414
Other languages
English (en)
Inventor
Venkata Sivakumar Bobba
Sunil POPHALE
Narayanan Murli
Shankar POL
Original Assignee
Zenvision Pharma Llp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zenvision Pharma Llp filed Critical Zenvision Pharma Llp
Publication of WO2022234593A1 publication Critical patent/WO2022234593A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Definitions

  • the present invention relates to a sublingual composition comprising nintedanib or salt thereof as an active agent, process of preparation thereof and method of using the same.
  • the present invention particularly relates to a sublingual composition comprising nintedanib or salt thereof and the use of said sublingual composition for the treatment of idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, systemic sclerosis-associated interstitial lung disease and cancer.
  • idiopathic pulmonary fibrosis chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype
  • ILDs chronic fibrosing interstitial lung diseases
  • Cancers are a large family of diseases that involve abnormal cell growth with the potential to invade or spread to other parts of the body. They form a subset of neoplasms.
  • a neoplasm or tumor is a group of cells that have undergone unregulated growth and will often form a mass or lump but may be distributed diffusely.
  • Idiopathic pulmonary fibrosis is a type of chronic scarring lung disease characterized by a progressive and irreversible decline in lung function. Symptoms typically include gradual onset of shortness of breath and a dry cough.
  • Nintedanib is a synthetic indolinone compound developed by Boehringer Ingelheim (BIBF 1120) that inhibits vascular endotheliam growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR), a group of tyrosine kinase inhibitors, under study as an anti-cancer agent, and also for slowing progression of IPF.
  • BIBF 1120 Boehringer Ingelheim
  • VEGFR vascular endotheliam growth factor receptor
  • FGFR fibroblast growth factor receptor
  • PDGFR platelet-derived growth factor receptor
  • Nintedanib is a kinase inhibitor.
  • Nintedanib is presented as the ethanesulfonate salt (esylate), with the chemical name lH-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4- [methyl[(4-methyl-l-piperazinyl)acetyl]amino]phenyl]amino]phenyl-methylene]-2-oxo- ,methylester, (3Z)-, ethanesulfonate (1:1).
  • the molecular formula of nintedanib is C31H33N5O4 C2H6O3S and a molecular weight of 649.76 g/mol.
  • Nintedanib is represented by compound of structural formula I.
  • Nintedanib esylate is a bright yellow powder. Nintedanib esylate capsule oral was first approved by U. S. FDA on October 15,
  • Eq lOOmg base and Eq 150mg base strengths and mainly used for the treatment of idiopathic pulmonary fibrosis (IPF), chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype and systemic sclerosisassociated interstitial lung disease (SSc- ILD).
  • IPF idiopathic pulmonary fibrosis
  • ILDs chronic fibrosing interstitial lung diseases
  • SSc- ILD systemic sclerosisassociated interstitial lung disease
  • U.S. Patent Nos. 9,907,756 and 10,105,323 discloses pharmaceutical formulation comprising lipid suspension of nintedanib monoethanesulphonate in soft gelatin capsule. Said patents disclose composition approved under brand name OFEV.
  • U.S. Patents No. 1,0154,990 discloses use of nintedanib monoethanesulphonate for treating systemic scleroderma.
  • U.S. publication No. 20190070160 discloses various dosage forms of nintedanib generically like oral, parenteral, buccal, vaginal, rectal, inhalation, insufflation, sublingual, intramuscular, intradermal, subcutaneous, topical, intranasal, intraperitoneal, intrathoracic, intralesional, paralesional, intravenous, epidural, intrathecal, or intracerebroventricular routes, or by injection into the tissue and/or joints; however said patent publication does not discloses or teaches specifically sublingual composition of nintedanib.
  • compositions are available in the form of soft capsules in Eq lOOmg base and Eq 150mg base strengths, said dosage form have several drawbacks such as low bioavailability, substantial first pass metabolism, pH sensitivity of nintedanib or salt thereof, formulations process associated problems, high dose, etc.
  • compositions do not disclose or claim low dose composition of comprising specific nintedanib or salt thereof intended for transmucosal, i.e., buccal / sublingual route administration which bypass first-pass metabolism.
  • nintedanib The commercially available product is capsule, oral as well as products known in the prior art disclosed different dosage forms of nintedanib have drawbacks such as but not limited to less low bioavailability, processability issues, and substantial first pass metabolism.
  • composition of present invention such as: i) Less bioavailability associated with prior art composition due to substantial first-pass metabolism can be overcome by newly developed sublingual composition, wherein said composition possess properties such as high therapeutic efficiency, storage stability and better patient compliance. ii) Further as the drug nintedanib or salt thereof is pH sensitive, in present invention, pH of the composition is maintained in acidic range by acidic agent which avoids formulations process associated problems.
  • the main object of the invention is to provide sublingual composition comprising: a) Nintedanib or salt thereof; and b) At least one pharmaceutically acceptable excipient.
  • the main object of the invention is to provide a sublingual composition comprising: a) Nintedanib or salt thereof; b) At least one diluent; and c) At least one pharmaceutically acceptable excipient.
  • Another object of the invention is to provide a sublingual composition
  • a sublingual composition comprising: a) 0.1-60% w/w of Nintedanib or salt thereof; b) 30-90% w/w of diluent; c) l%-40% w/w of acidifying agents; d) 5-35% w/w of solubility enhancer; e) 0.1-5% w/w of lubricant; and f) Optionally 1 %- 15% w/w of disintegrant.
  • Another object of the invention is to provide a sublingual tablet composition
  • a sublingual tablet composition comprising: a) 0.1-60% w/w of Nintedanib or salt thereof; b) 30-90% w/w of diluent; c) l%-40% w/w of acidifying agents; d) 5-35% w/w of solubility enhancer; e) 0.1-5% w/w of lubricant; and f) Optionally 1 %- 15% w/w of disintegrant; and wherein the sublingual tablet composition is optionally coated.
  • a further object of the invention is to provide a process for the preparation of a sublingual composition comprising nintedanib or salt thereof which comprises steps of: a) Co-sifting and mixing one or more diluents into suitable vessel; b) Preparing binder solution; c) Adding nintedanib or salt thereof to the binder solution obtained in step (b); d) Granulating mixture of step (a) with binder solution obtained in step (c); e) Drying granules obtained in step (d); f) Optionally blending dried granules of step (e) with disintegrant; g) Lubricating dried granules obtained in step (e) or (f); h) Optionally compressing lubricated blend obtained in step (g) to get sublingual tablet dosage form; and i) Optionally coating the sublingual tablet dosage form obtained in step (g).
  • a further object there is provided a sublingual compositions of nintedanib or salt thereof for the treatment of idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, systemic sclerosis-associated interstitial lung disease and cancer.
  • ILDs chronic fibrosing interstitial lung diseases
  • an invention provides sublingual composition comprising nintedanib or salt thereof and at least one pharmaceutically acceptable excipient.
  • an invention also relates to process of preparation of a sublingual composition comprising nintedanib or salt thereof.
  • in another aspect of the present invention is to provide sublingual film, sublingual tablet, sublingual spray, sublingual granule, sublingual powder or sublingual disc, buccal tablet of nintedanib or salt thereof comprising at least one pharmaceutically acceptable excipient.
  • an invention provides a sublingual composition comprising: a) Nintedanib or salt thereof; and b) Optionally other suitable pharmaceutically acceptable excipients.
  • an invention provides a sublingual composition
  • a sublingual composition comprising: a) Nintedanib or salt thereof; b) At least one diluent; and c) Optionally other suitable pharmaceutically acceptable excipients.
  • an invention provides a sublingual composition
  • a sublingual composition comprising: a) 0.1-60% w/w of Nintedanib or salt thereof; b) 30-90% w/w of diluent; c) l%-40% w/w of acidifying agents; d) 5-35% w/w of solubility enhancer; e) 0.1-5% w/w of lubricant; and f) Optionally 1 %- 15% w/w of disintegrant.
  • an invention provides a sublingual tablet composition
  • a sublingual tablet composition comprising: a) 0.1-60% w/w of Nintedanib or salt thereof; b) 30-90% w/w of diluent; c) l%-40% w/w of acidifying agents; d) 5-35% w/w of solubility enhancer; e) 0.1-5% w/w of lubricant; and f) Optionally 1 %- 15% w/w of disintegrant; and
  • sublingual tablet composition is optionally coated.
  • a process for the preparation of a sublingual composition comprising nintedanib or salt thereof which comprises steps of: a) Co-sifting and mixing one or more diluents into suitable vessel; b) Preparing binder solution; c) Adding nintedanib or salt thereof to the binder solution obtained in step (b); d) Granulating mixture of step (a) with binder solution obtained in step (c); e) Drying granules obtained in step (d); f) Optionally blending dried granules of step (e) with disintegrant; g) Lubricating dried granules obtained in step (e) or (f); h) Compressing lubricated blend obtained in step (g) to get sublingual tablet dosage form; and i) Optionally coating the sublingual tablet dosage form obtained in step (g).
  • in another aspect of the present invention is to provide a sublingual compositions of nintedanib or salt thereof for the treatment of idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, systemic sclerosis- associated interstitial lung disease and cancer.
  • ILDs chronic fibrosing interstitial lung diseases
  • nintedanib is used in broad sense to include not only “nintedanib” per se but also its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, derivatives, isomers, polymorphs, prodrugs thereof.
  • nintedanib ethanesulfonate salt esylate.
  • nintedanib or salt thereof according to present invention may be present in an amount from about 0.1% to about 60% by weight with respect to total weight of the pharmaceutical composition.
  • the nintedanib or salt thereof according to present invention may be present in an amount from about Eq 0.1 mg base to about Eq 150mg base with respect to total weight of the pharmaceutical composition.
  • salt thereof or “pharmaceutically acceptable salt” refers to salts derived from a variety of organic and inorganic counter ions.
  • nintedanib salt examples include but not limited as, examples of physiologically acceptable salts include particularly for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids.
  • Acids which may be used for this purpose include for example hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, maleic acid, ethanesulfonic acid (esylic acid) or methanesulphonic acid.
  • Physiologically acceptable salts of a nitrogen atom or an amino group include (a) acid addition salts formed with inorganic acids, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acids, phosphoric acid, nitric acid and the like; (b) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, isethionic acid, lactobionic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, ethanesulfonic acid (esylic acid), methanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic
  • composition as in sublingual composition, is intended to encompass a drug product comprising nintedanib or salts thereof, and other inert ingredient(s) (pharmaceutically acceptable excipients).
  • composition is synonymous with “formulation” and “dosage form”.
  • sublingual composition refers to a composition selected from but not limited to sublingual tablet, sublingual spray, sublingual granule, sublingual powder, sublingual disc, sublingual film/ strip, buccal tablet, buccal film/strip, or mucoadhesive film/strip, or the like.
  • sublingual administration refers to a composition intended for placement of the drug under the tongue, within the oral mucosal environment and drug reaches directly in to the blood stream through the ventral surface of the tongue and floor of the mouth.
  • the drug solutes are rapidly absorbed into the reticulated vein which lies underneath the oral mucosa, and transported through the facial veins, internal jugular vein.
  • treating refers to obtaining desired pharmacological and/or physiological effect.
  • the effect can be therapeutic, which includes achieving, partially or substantially, one or more of the following results: partially or totally reducing the extent of the disease, disorder or syndrome; ameliorating or improving a clinical symptom or indicator associated with the disorder or delaying, inhibiting or decreasing the likelihood of the progression of the disease, disorder or syndrome.
  • an invention provides a sublingual composition comprising nintedanib or salts thereof.
  • a sublingual composition of the present invention may contain one or more pharmaceutically acceptable excipients.
  • the one or more pharmaceutically acceptable excipient according to present invention may be selected from the group consisting of diluents, disintegrants, binders, solubilizing agent, surfactant, absorption enhancer, bioadhesive agents or mucoadhesion promoting agent, polymers or release modifying agent, carriers, plasticiser, penetration enhancer, bases, lubricant, glidant, acidic agent, basic agent, chelators, sweeteners, flavoring agent, pH regulating agent, preservatives, antioxidants, coloring agents, solvents, taste masking agent, antifoaming agents, flow agents and opacifiers, antiadherent, stabilizing agent, antistatic agent, viscosity adjuster and coating agent.
  • diluent or filler include but not limited to group comprising of citric acid, mannitol, microcrystalline cellulose, carboxymethyl cellulose (carmellose), sodium carboxymethyl cellulose (carmellose sodium), corn starch, potato stach, anhydrous lactose, lactose monohydrate and the mixtures thereof.
  • the diluents are selected from citric acid and mannitol or combination thereof.
  • the diluents according to present invention may be present in an amount from about 10% to about 95% by weight with respect to total weight of the pharmaceutical composition, preferably 30% to 90% w/w.
  • disintegrants include but not limited to group comprising of croscarmellose sodium, croscarmellose potassium, carboxymethyl cellulose, chitosan, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, crospovidone, hydroxypropyl cellulose, microcrystalline cellulose, methyl cellulose, starch, sodium starch glycolate, light anhydrous silicic acid, low substituted hydroxypropylcellulose, lactose, sucrose, starch, silicified microcrystalline cellulose, polarcilin potassium, crosslinked polyvinylpyrrolidone, ethyl hydroxyethyl cellulose, modified cellulose gum; moderately cross-linked starch, modified starch, hydroxylpropyl starch and pregelatinized starch; calcium alginate, sodium alginate, alginic acid, chitosan, colloidal silicon dioxide, docusate sodium, guar gum, agar, locust bean, karaya, pectin and
  • the disintegrants according to present invention may be present in an amount from about 1 %- 15% by weight with respect to total weight of the pharmaceutical composition.
  • binders include but not limited to group comprising of microcrystalline cellulose, alginic acid, potato starch, com starch, wheat starch, ethyl cellulose, gelatin, cellulose-based polymers like methylcellulose, ethylcellulose, hydroxylated derivatives, hydroxyethyl cellulose, carboxymethyl cellulose sodium, hydroxymethyl cellulose, hydroxypropyl cellulose, microcrystalline cellulose, dihydroxy propylcellulose, hypromellose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetosuccinate, acrylic polymers and polyethylene glycols, magnesium aluminium silicate, maltodextrin, methyl cellulose, povidone, copovidone, sodium starch glycolate, starch, trehalose, flurane, sucrose, D-mannitol, sodium alginate, cellulose gum, pregelatinized starch, guar gum, pullulan, gum arabic, bentonites, sugars, invert
  • solubilizing agents or solubility enhancer include but not limited to group comprising of cyclodextrin and/or its derivatives, 2-Hydroxypropyl-beta-cyclodextrin (Kleptose), polyethylene glycol, polyvinylpyrrolidone, dextran, sugars such as sucrose, lactose or dextrose, mannitol, sorbitol or lactitol, sodium chloride or mixture thereof.
  • Kleptose 2-Hydroxypropyl-beta-cyclodextrin
  • dextran dextran
  • sugars such as sucrose, lactose or dextrose
  • mannitol mannitol
  • sorbitol or lactitol sodium chloride or mixture thereof.
  • solubilizing agents or solubility enhancer according to present invention may be present in an amount from about 1% to about 40% by weight with respect to total weight of the pharmaceutical composition, preferably 5-35% w/w.
  • surfactants include but not limited to group comprising of cationic, anionic, nonionic or amphoteric agents, polysorbate, sodium lauryl sulphate, polyoxyethylene, polyoxypropylene glycol, the monooleate, the monolaurate, the monopalmitate, the monostearate, the trioleate, the tristearate or any other ester of polyoxyethylenated sorbitan, glycerides of polyoxyethylenated fatty acids, poloxamers, ethylene oxide/propylene oxide block copolymers, lecithin, stearyl alcohol, cetearyl alcohol, cholesterol, polyoxyethylenated castor oil, fatty alcohol polyoxyethylenated ethers, and polyoxyethylenated stearates, cetyl alcohol, spans and tweens, ethoxylated oils, including ethoxylated castor oils, such as cremophor or mixture thereof.
  • absorption enhancer examples include but not limited to group comprising of sodium lauryl sulphate, sodium caprate or chitosans, and also P-glycoprotein (P-gp) inhibitors, such as polysorbates, sorbitan esters, poloxamer block copolymers, PEG-35 castor oil, PEG-40 hydrogenated castor oil, caprylocaproyl macrogol-8 glycerides, PEG-8 caprylic/capric glycerides, dioctyl sulfosuccinate, polyethylene lauryl ether, ethoxydiglycol, propylene glycol mono-di-caprylate, glycerol monocaprylate, glyceryl fatty acids (Cs-Cis) ethoxylated, oleic acid, linoleic acid, glyceryl caprylate/caprate, glyceryl monooleate, glyceryl monolaurate, caprylic/capric
  • bioadhesive agents or mucoadhesion promoting agents include but not limited to group comprising of carbomers, sodium carboxymethylcellulose, sodium alginate, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, ethylcellulose, gelatine, guar gum, polyethylene oxide, and dextran, carbopol 934 P, methocel, polycarbophil, sodium hyaluronate and other natural or synthetic bioadhesives, cellulose derivatives such as modified cellulose gum and, more particularly, methyl cellulose, ethyl hydroxyethyl cellulose, carboxymethyl cellulose, starch derivatives such as modified starch, sodium starch glycolate and, more particularly, moderately cross-linked starch; acrylic polymers, polyvinylpyrrolidone; polyethylene oxide (PEO), chitosan (poly-(D-glucosamine); natural polymers such as gelatin, sodium alginate, pect
  • polymers or release modifying agent according to present invention include but not limited to water-soluble, water-insoluble and/or biodegradable polymers or combination thereof.
  • Water soluble polymers according to present invention include but are not limited to group comprising of polyethylene oxide (PEO), pullulan, water-soluble derivatives of cellulose: alkylcelluloses hydroxyalkylcelluloses and hydroxyalkylalkylcelluloses, such as methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxypropylmethylcellulose, hydroxybutylmethylcellulose, cellulose esters and hydroxyalkylcellulose esters such as cellulose acetate phthalate (CAP), hydroxypropylmethylcellulose (HPMC), carboxyalkylcelluloses, carboxyalkylalkylcelluloses, carboxyalkylcellulose esters such as carboxymethylcellulose and their alkali metal salts, polyethylene glycol, polydextrose, polyvinyl pyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, poloxamers, sodium alginate, propylene glycol alginate, carrageenan, polyethylene
  • PEO polyethylene oxide
  • Water insoluble polymers according to present invention include, but are not limited to group comprising of ethyl cellulose, carboxymethylcellulose, cellulose acetate, nitrocellulose, hydroxypropyl ethyl cellulose, cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, acrylic polymers, acrylic resin material, vinyl acetate, sodium sulphonated polyesters, carboxylated acrylics, trimethylpentanediol/adipic acid/glycerin cross polymer, polyglycerol-2-diisostearate/IPDI copolymer, carboxylated vinyl acetate copolymer, vinylpyrrolicone/vinyl acetate/alkylaminoacrylate terpolymers, vinylpyrrolidone/vinyl acetate copolymer, polyoxyethylene/polyoxypropylene polymers, copolymers or block copolymers, carbamer, Polyamines include homo and copolymers of dimethylamino
  • Biodegradable polymers according to present invention include but not limited to group comprising of poly(glycolic acid) (PGA), poly(lactic acid) (PLA), polydioxanes, polyoxalates, poly(a-esters), polyanhydrides, polyacetates, polycaprolactones, poly(orthoesters), polyamino acids, polyaminocarbonates, polyurethanes, polycarbonates, polyamides, poly (alkyl cyanoacrylates), and mixtures and copolymers thereof.
  • PGA poly(glycolic acid)
  • PLA poly(lactic acid)
  • PDA polydioxanes
  • polyoxalates poly(a-esters)
  • polyanhydrides polyacetates
  • polycaprolactones poly(orthoesters)
  • polyamino acids polyaminocarbonates
  • polyurethanes polycarbonates
  • polyamides polyamides
  • Additional useful polymers include, stereopolymers of L- and D-lactic acid, copolymers of bis(p- carboxyphenoxy) propane acid and sebacic acid, sebacic acid copolymers, copolymers of caprolactone, poly (lactic acid)/poly (glycolic acid)/poly ethyleneglycol copolymers, copolymers of polyurethane and (poly(lactic acid), copolymers of polyurethane and poly(lactic acid), copolymers of a-amino acids, copolymers of a-amino acids and caproic acid, copolymers of a-benzyl glutamate and polyethylene glycol, copolymers of succinate and poly(glycols), polyphosphazene, polyhydroxy-alkanoates or mixtures thereof.
  • the examples of carriers according to present invention include but not limited to group comprising of mannitol, carbohydrates, e.g., sugars, such as lactose, and sugar alcohols, such as mannitol, sorbitol and xylitol; pharmaceutically-acceptable inorganic salts, such as sodium chloride.
  • Water soluble carrier particles may also comprise the weakly acidic, and/or weakly acidic buffer forming materials such as citric acid and/or sodium citrate, insoluble or sparingly soluble in water, such as dicalcium phosphate anhydrate, dicalcium phosphate dihydrate, tricalcium phosphate, calcium carbonate, and barium sulphate; starch and pre-gelatinised starch; bioadhesive and mucoadhesive materials, such as polyvinylalcohol, polyvinylpyrrolidine, crosslinked polyvinylpyrrolidone and croscarmellose sodium and other polymers, such as microcrystalline cellulose, hydroxypropyl cellulose, water, buffer, saline, buffered saline, dextrose solution, propylene glycol, polyethylene glycols, miglyol or mixtures thereof.
  • weakly acidic, and/or weakly acidic buffer forming materials such as citric acid and/or sodium citrate, insoluble or sparingly soluble
  • plasticizers include but not limited to group comprising of polyalkylene oxides, such as polyethylene glycols, polypropylene glycols, polyethylene-propylene glycols, organic plasticizers with low molecular weights, such as glycerol, glycerol monoacetate, diacetate or triacetate, triacetin, polysorbate, cetyl alcohol, propylene glycol, sorbitol, sodium diethylsulfosuccinate, triethyl citrate, tributyl citrate, fatty acid esters, such as glyceryl oleate, polyalcohols, sorbitan esters, citric acid esters, polyvinyl alcohol, polyvinyl methyl ether, triacetin; mannitol, xylitol, and sorbitol or mixtures thereof.
  • polyalkylene oxides such as polyethylene glycols, polypropylene glycols, polyethylene-propylene glycols, organic plastic
  • penetration enhancers include but not limited to group comprising of bile salts, such as sodium cholate, sodium glycocholate, sodium glycodeoxycholate, taurodeoxycholate, sodium deoxycholate, sodium lithocholate chenocholate, chenodeoxycholate, ursocholate, ursodeoxy-cholate, hyodeoxycholate, dehydrocholate, glycochenocholate, taurochenocholate, and taurochenodeoxy cholate; sodium dodecyl sulfate (SDS), dimethyl sulfoxide (DMSO), N-lauroyl sacrcosine, sorbitan monolaurate, stearyl methacrylate, N-dodecylazacycloheptan-2-one, N-dodecyl-2- pyrrolidinone, N-dodecyl-2-piperidinone, 2-(l-nonyl)-l,3-dio
  • bases according to present invention include but not limited to group comprising of hydrophilic bases include, for example, polyethylene glycol, polyvinylpyrrolidone, D-mannitol, D-sorbitol, xylitol, lactose, white sugar, maltose anhydrous, D-fructose, dextran, glucose, polyoxyethylene curing It may be at least one selected from the group consisting of castor oil, polyoxyethylene polyoxypropylene glycol, polyoxyethylene sorbitan higher fatty acid ester, citric acid, tartaric acid, glycine, b-alanine, lysine hydrochloride and meglumine or mixture thereof.
  • hydrophilic bases include, for example, polyethylene glycol, polyvinylpyrrolidone, D-mannitol, D-sorbitol, xylitol, lactose, white sugar, maltose anhydrous, D-fructose, dextran, glucose, polyoxyethylene cu
  • lubricant according to present invention include but not limited to group comprising of calcium stearate, magnesium stearate, Sodium stearyl fumarate, fumaric acid, calcium stearate, polyethylene glycol, sodium benzoate, potassium benzoate, sodium lauryl sulphate, talc, colloidal silica, sucrose fatty acid esters, stearic acid, zinc stearate, hydrogenated vegetable oil, mineral oil, glyceryl behenate, polyoxyethylene glycols, sodium benzoate, dimethicone or liquid paraffin, or mixture thereof.
  • the lubricant according to present invention may be present in an amount from about 0.1% to about 10% by weight with respect to total weight of the pharmaceutical composition, preferably 0.1-5% w/w.
  • glidant examples include but not limited to group comprising of colloidal silica, pyrogenic silica, hydrated sodium silicoaluminate, magnesium stearate, sodium stearyl fumarate, fumed silica (colloidal silicon dioxide), starch, talc, calcium phosphate tribasic, powdered cellulose, magnesium oxide; magnesium silicate, magnesium trisilicate, stearic acid, calcium stearate or mixture thereof.
  • acidic agents or acidifying agents according to present invention include but not limited to group comprising of citric acid maleic acid, tartaric acid, fumaric acid, adipic acid, succinic acid, lactic acid, glycolic acid, alpha-hydroxy acids, ascorbic acid and amino acids, anhydrides, salts and derivatives of these acids or mixture thereof.
  • the acidic agents or acidifying agents according to present invention may be present in an amount from about 1% to about 40% by weight with respect to total weight of the pharmaceutical composition.
  • the examples of basic agents according to present invention include but not limited to group comprising of potassium carbonate, sodium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, arginine carbonate, glycine carbonate or lithium carbonate, calcium carbonate, ammonium carbonate, L-lysine carbonate, sodium glycine carbonate, sodium carbonates of amino acids, anhydrous sodium perborate, effervescent perborate, sodium perborate monohydrate, sodium percarbonate, sodium dichloroisocyanurate, sodium hypochlorite, calcium hypochlorite, tris, tartrate, acetate, phosphate or mixture thereof.
  • chelators include but not limited to group comprising of ethylene diamine tetra acetic acid (EDTA), proteins, polysaccharides, polynucleic acids, glutamic acid, histidine, organic diacids, polypeptides, phytochelatin, hemoglobin, chlorophyll, humic acid, phosphonates, transferrin, desferrioxamine, and combinations thereof.
  • EDTA ethylene diamine tetra acetic acid
  • sweeteners include but not limited to group comprising of dipotassium glycyrrhizinate, aspartame, stevia, thaumatin, saccharose, glucose, maltose, galactose, and artificial sweeteners, such as acesulfame potassium, sodium saccharin, cyclamates, sucralose, sodium saccharinate, neohesperidine dihydrochalcone, monoammonium glycyrrhizinate, Thaumatic, dextrose, invert sugar, fructose, Stevia Rebaudiana (Stevioside); sugar alcohols such as sorbitol, mannitol, xylitol, and the like.
  • flavoring agent include but not limited to group comprising of fruit flavor, peppermint flavor, lemon, lemon-lime, orange, sour cherry, flavor of mint, honey lemon, vanilla, citrus oil, grapefruit grape, menthol, cranberry, vanilla berry, bubble gum, cherry, alpha-citral, beta-citral, decanal, aldehyde C-8, aldehyde C-9, aldehyde C-12, and volatile oils, synthetic flavor oils, flavoring aromatics, oils, liquids, oleoresins or extracts derived from plants, leaves, flowers, fruits, stems and combinations thereof mint oils, cocoa, and citrus oils such as lemon, orange, grape, lime, cinnamon oil, oil of wintergreen, peppermint oils, clove oil, bay oil, anise oil, eucalyptus, thyme oil, cedar leave oil, oil of nutmeg, oil of sage, oil of bitter almonds and cassia oil, grapefruit and fruit essences including apple,
  • pH regulating agent examples include but not limited to group comprising of hydrochloric acid, fumarate, citrate, phosphate, carbonate, tartrate, acetate, amino acid, citric acid and sodium citrate or potassium citrate, sodium hydroxide, monoethanolamine, diethanolamine, sodium bicarbonate or potassium bicarbonate, sodium phosphate, tartaric acid, propionic acid, lactic acid, maleic acid, succinic acid, phosphoric acid, boric acid, succinic acid/mono sodium succinate, glycine/sodium glycine, malic acid/sodium malate, phosphoric acid/sodium phosphate, fumaric acid/sodium fumarate, monosodium phosphate/disodium phosphate, and boric acid/sodium borate and monosodium glutamate or mixture thereof.
  • preservatives according to present invention include but not limited to group comprising of phenethyl alcohol, benzyl alcohol, p-hydroxybenzoate esters, chlorobutanol, dehydroacetic acid, sorbic acid or mixtures thereof.
  • antioxidants include but not limited to group comprising of butylated hydroxytoluene (BHT), hydrogen sulfite, ascorbic acid, sodium ascorbate, erythorbic acid, sodium nitrite, propyl gallate (PG), butylhydroxyanisol (BHA), sodium bisulfite, sodium pyrosulfite, citric acid, and edetate sodium, Sodium bicarbonate, sodium citrate, sodium citrate, sodium metabisulfate, sodium tartrate, sodium sulphite, sodium metabisulphite, Sodium sulfate, potassium metabisulphite, potassium, bisulphite, potassium sulphite, tocopherol, tocopherol ester derivatives, 2- mercaptobenzimidazole, thiols (e.g., aurothioglucose, dihydrolipoic acid, propylthiouracil, thioredoxin, glutathione, glutathione, glutathione, glut
  • coniferyl benzoate uric acid, mannose, selenium (e.g., selenium-methionine), stilbenes (e.g. stilbene oxide and trans-stilbene oxide), superoxide dismutase (SOD) or mixtures thereof.
  • the examples of the coloring agents according to present invention include but not limited to group comprising of carmine, caramel, b-carotene, titanium oxide, talc, riboflavin sodium phosphate, hydrogenated starch hydrolysate, food, drug and cosmetic colors (FD&C), drug and cosmetic colors (D&C), or external drug and cosmetic colors (Ext. D&C).
  • yellow aluminum lake natural pigments examples: beta-carotene, chlorophyll, and colcothar
  • water- insoluble lake pigments examples: aluminum salts of the above water-soluble edible tar pigments
  • water-soluble edible tar pigments examples: edible pigments such as food red No. 2, food red No. 3, food yellow No: 4, food yellow No. 5, food blue No. 1, and food blue No. 2
  • blue lake titanium dioxide
  • natural coloring agents such as grape skin extract, beet red powder, annato, carmine, turmeric, paprika or mixtures thereof.
  • solvents according to present invention include but not limited to group comprising of aqueous or inert organic solvents or inorganic acids, alcohols, ketones, esters, ethers, aliphatic hydrocarbons, halogenated solvents, cycloaliphatic solvents, aromatic solvents, heterocyclic solvents, and mixtures thereof.
  • Typical solvents include acetone, diacetone alcohol, methanol, ethanol, isopropyl alcohol, butyl alcohol, methyl acetate, ethyl acetate, isopropyl acetate, n-butyl acetate, methyl isobutyl ketone, methyl ethyl ketone, methylene chloride, methyl propyl ketone, n-hexane, n-heptane, ethylene glycol monoethyl ether, ethylene glycol monoethyl acetate, methylene dichloride, ethylene dichloride, propylene dichloride, carbon tetrachloride, nitroethane, nitropropane, tetrachloroethane, ethyl ether, isopropyl ether, cyclohexane, cyclooctane, benzene, toluene, naphtha, 1,4-dioxan
  • the examples of taste masking agent according to present invention include but not limited to group comprising of ionic exchange resins including a water-insoluble organic or inorganic matrix material having covalently bound functional groups that are ionic or capable of being ionized under appropriate conditions.
  • the organic matrix may be synthetic (e.g., polymers or copolymers or acrylic acid, methacrylic acid, sulfonated styrene or sulfonated divinylbenzene) or partially synthetic (e.g., modified cellulose or dextrans).
  • the inorganic matrix may be, for example, silica gel modified by the addition of ionic groups.
  • Most ion exchange resins are cross-linked by a crosslinking agent, such as divinylbenzene, sodium bicarbonate, cyclodextrin inclusion compounds, adsorbates or mixture thereof.
  • anti-foaming agents include but not limited to group comprising of certain alcohols (cetostearyl alcohol), insoluble oils (castor oil), stearates, polydimethylsiloxanes and other silicones derivatives, ether and glycols or mixture thereof.
  • flow agents and opacifiers include but not limited to group comprising of such as the oxides of magnesium, aluminum, silicon, titanium or mixture thereof
  • antiadherent include but not limited to group comprising of talc, corn starch, colloidal silica, DL-leucine, sodium lauryl sulphate, stearates or mixture thereof.
  • stabilizing agent include but not limited to group comprising of tocopherol, cyclodextrin tetrasodium edetate, nicotinamide, thermo-setting gels such as pectin, carageenan, and gelatin, yellow ferric oxide, red ferric oxide, black iron oxide or mixture thereof.
  • antistatic agents include but not limited to group comprising of micronized or nonmicronized talc, colloidal silica, treated silica or precipitated silica or mixtures thereof.
  • viscosity adjusters include but not limited to group comprising of alginate, carrageenan, hydroxypropyl methyl cellulose, locust bean gum, guar gum, xanthan gum, dextran, gum arabic, gellan gum or mixtures thereof.
  • coating agents according to present invention include but not limited to a film coating agent or the like for example, an opadry film coating agents or film coating agent known in the prior art for sublingual dosage form.
  • in another aspect of the present invention is to provide process of manufacturing sublingual compositions of nintedanib or salt thereof along with one or more pharmaceutically acceptable excipient.
  • the process like solvent casting, solvent evaporation, hot-melt extrusion, semisolid casting method, rolling method may be used in the preparation of sublingual film.
  • the process like direct compression, dry granulation, wet granulation, spray granulation, extrusion-spheronization may be used in the preparation of sublingual tablet.
  • nintedanib or salt thereof and process of manufacturing has been optimized in view of the need in the treatment of idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, systemic sclerosis-associated interstitial lung disease and cancer.
  • ILDs chronic fibrosing interstitial lung diseases
  • nintedanib or salt thereof in the treatment of idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, systemic sclerosis-associated interstitial lung disease and cancer are placed under the tongue and nintedanib or salt thereof reaches directly into the blood stream through the ventral surface of the tongue and floor of the mouth.
  • the nintedanib solutes are rapidly absorbed into the reticulated vein which lies underneath the oral mucosa, and transported through the facial veins, internal jugular vein, and braciocephalic vein and then drained into systemic circulation.
  • sublingual composition of nintedanib or salt thereof according to present invention prevents the degradation of Nintedanib in to the gastrointestinal tract (GIT), liver i.e. bypasses the first pass metabolism and desired therapeutic level of nintedanib is reached in the blood circulation which is required in the treatment of idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, systemic sclerosis- associated interstitial lung disease and cancer.
  • GIT gastrointestinal tract
  • ILDs chronic fibrosing interstitial lung diseases
  • the sublingual composition of nintedanib or salt thereof according to present invention provide immediate onset of action, better ease of self-administration without pain and without help of trained medical professional; therefore, provides better patient compliance in the treatment of idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype and cancer.
  • ILDs interstitial lung diseases
  • the sublingual or buccal composition of nintedanib or salt thereof according to present invention may be evaluated for the parameters like dissolution data, weight variation, mg content, hardness, friability, disintegration time, wetting time, thickness, tensile strength, folding endurance, surface pH, and swelling index.
  • the sublingual composition of nintedanib or salt thereof according to present invention can be packaged in suitable air-tight containers and moisture proof packs.
  • Packaging may include but not limited to high density polyethylene bottle, aluminum blister package.
  • the container material or packaging material of the present invention does not affect the quality of the preparation or does not allow diffusion of any kind into or across the material of the container into the preparation.
  • an invention provides a sublingual composition comprising: a) Nintedanib or salt thereof; and b) optionally other suitable pharmaceutically acceptable excipients.
  • an invention provides a sublingual composition
  • a sublingual composition comprising: a) Nintedanib or salt thereof; b) At least one diluent; and c) Optionally other suitable pharmaceutically acceptable excipients.
  • an invention provides a sublingual composition
  • a sublingual composition comprising: a) 0.1-60% w/w of Nintedanib or salt thereof; b) 30-90% w/w of diluent; c) l%-40% w/w of acidifying agents; d) 5-35% w/w of solubility enhancer; e) 0.1-5% w/w of lubricant; and f) Optionally 1 %- 15% w/w of disintegrant.
  • an invention provides a sublingual tablet composition
  • a sublingual tablet composition comprising: a) 0.1-60% w/w of Nintedanib or salt thereof; b) 30-90% w/w of diluent; c) l%-40% w/w of acidifying agents; d) 5-35% w/w of solubility enhancer; e) 0.1-5% w/w of lubricant; and f) Optionally 1 %- 15% w/w of disintegrant; and
  • sublingual tablet composition is optionally coated.
  • an invention provides process for the preparation of a sublingual composition comprising nintedanib or salt thereof which comprises steps of: a) Co-sifting and mixing one or more diluents into suitable vessel; b) Preparing binder solution; c) Adding nintedanib or salt thereof to the binder solution obtained in step (b); d) Granulating mixture of step (a) with binder solution obtained in step (c); e) Drying granules obtained in step (d); f) Optionally blending dried granules of step (e) with disintegrant; g) Lubricating dried granules obtained in step (e) or (f); h) Optionally Compressing lubricated blend obtained in step (g) to get sublingual tablet dosage form; and i) Optionally coating the sublingual tablet dosage form obtained in step (g).
  • an invention provides sublingual compositions of nintedanib or salt thereof for the treatment of idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, systemic sclerosis-associated interstitial lung disease and cancer.
  • ILDs chronic fibrosing interstitial lung diseases
  • Example: 1 Wet granulation approach.
  • Citric acid and mannitol co-sifted through sieve no.20#;
  • Binder solution 0.1N HCL solution was taken and 2-Hydroxypropyl-beta-cyclodextrin (Kleptose) was added to it and stirred well, tartaric acid was added to it and stirred until it dissolves completely. Solution was heated up to 50-60°C and API Nintedanib esylate was added to it and stirred well, it forms clear orange-yellow solution;
  • Magnesium stearate was sifted through sieve no.60# and lubricated with dried granules; and 9. Blend was compressed using 6.5mm round shape punch.
  • Dissolution data 0.1N HC1 solution, 900mL, Paddle, 100 rpm
  • FBP Fluidized Bed processing
  • Blend was compressed using 6.5mm round shape punch.
  • Citric acid and Mannitol co- sifted through sieve no.20#;
  • Binder solution 0.1N HCL solution was taken and 2-Hydroxypropyl-beta-cyclodextrin (Kleptose) was added to it and stirred well, tartaric acid was added to it and stirred until it dissolves completely. Solution was heated up to 50-60°C and API Nintedanib esylate was added to it and stirred well, it forms clear orange-yellow solution; 4. Co-Sifted citric acid and Mannitol (Peralitol) loaded into Fluidized Bed processing (FBP) machine;
  • FBP Fluidized Bed processing
  • Magnesium stearate was sifted through sieve no.60# and lubricated with above blend.
  • Blend was compressed using 6.5mm round shape punch.
  • Example: 4 Wet granulation approach.
  • Binder solution 0.1N HCL solution was taken and 2-Hydroxypropyl-beta-cyclodextrin (Kleptose) was added to it and stirred well, tartaric acid was added to it and stirred until it dissolves completely. Solution was heated up to 50-60°C and API Nintedanib esylate was added to it and stirred well, it forms clear orange-yellow solution;
  • Magnesium stearate was sifted through sieve no.60# and lubricated with dried granules;
  • Blend was compressed using 6.5mm round shape punch. Dissolution data: 0.1N HC1, 900mL, paddle, lOOrpm.
  • Example: 5 Wet granulation approach.
  • Binder solution 0.1N HCL solution was taken and 2-Hydroxypropyl-beta-cyclodextrin (Kleptose) was added to it and stirred well, tartaric acid was added to it and stirred until it dissolves completely. Solution was heated up to 50-60°C and API Nintedanib esylate was added to it and stirred well, it forms clear orange-yellow solution;
  • Magnesium stearate was sifted through sieve no.60# and lubricated with dried granules;
  • Blend was compressed using 6.5mm round shape punch.
  • Dissolution data 0.1N HC1 solution, 900mL, lOOrpm, paddle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition sublinguale comprenant nintedanib ou un sel de celui-ci en tant qu'agent actif, son procédé de préparation et son procédé d'utilisation pour le traitement de la fibrose pulmonaire idiopathique, de maladies pulmonaires interstitielles fibrotiques chroniques (ILD)) avec un phénotype progressif, une maladie pulmonaire interstitielle associée à la sclérose systémique et un cancer.
PCT/IN2022/050414 2021-05-02 2022-05-02 Compositions sublinguales comprenant nintedanib ou un sel de celui-ci WO2022234593A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202021047679 2021-05-02
IN202021047679 2021-05-02

Publications (1)

Publication Number Publication Date
WO2022234593A1 true WO2022234593A1 (fr) 2022-11-10

Family

ID=83933033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2022/050414 WO2022234593A1 (fr) 2021-05-02 2022-05-02 Compositions sublinguales comprenant nintedanib ou un sel de celui-ci

Country Status (1)

Country Link
WO (1) WO2022234593A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010144943A1 (fr) * 2009-05-20 2010-12-23 Ozpharma Pty Ltd Formulations thérapeutiques améliorées
WO2017062694A1 (fr) * 2015-10-07 2017-04-13 Diane Tang-Liu Compositions et méthodes de traitement de troubles fibreux de la peau
WO2022061120A1 (fr) * 2020-09-18 2022-03-24 Dispersol Technologies, Llc Dispersions solides contenant du nintedanib amorphe, leur synthèse et leur utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010144943A1 (fr) * 2009-05-20 2010-12-23 Ozpharma Pty Ltd Formulations thérapeutiques améliorées
WO2017062694A1 (fr) * 2015-10-07 2017-04-13 Diane Tang-Liu Compositions et méthodes de traitement de troubles fibreux de la peau
WO2022061120A1 (fr) * 2020-09-18 2022-03-24 Dispersol Technologies, Llc Dispersions solides contenant du nintedanib amorphe, leur synthèse et leur utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIU HONGFEI, DU KUNYU, LI DONGLI, DU YI, XI JUMEI, XU YING, SHEN YAN, JIANG TAO, WEBSTER THOMAS J.: "A high bioavailability and sustained-release nano-delivery system for nintedanib based on electrospray technology", INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. Volume 13, pages 8379 - 8393, XP055922506, DOI: 10.2147/IJN.S181002 *
WIND SVEN, SCHMID ULRIKE, FREIWALD MATTHIAS, MARZIN KRISTELL, LOTZ RALF, EBNER THOMAS, STOPFER PETER, DALLINGER CLAUDIA: "Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib", CLINICAL PHARMACOKINETICS., ADIS INTERNATIONAL LTD., AUCKLAND, NZ, vol. 58, no. 9, 1 September 2019 (2019-09-01), NZ , pages 1131 - 1147, XP093005331, ISSN: 0312-5963, DOI: 10.1007/s40262-019-00766-0 *

Similar Documents

Publication Publication Date Title
JP5600747B2 (ja) 口腔内分散性製剤
JP6054940B2 (ja) １−（３−（２−（１−ベンゾチオフェン−５−イル）エトキシ）プロピル）アゼチジン−３−オールまたはその塩を含有する固形医薬組成物
JP2008523044A (ja) 医薬品有効成分を安定化する組成物および方法
PT1998762E (pt) Forma farmacêutica sólida contendo um agente activo de sabor mascarado
JPWO2005055989A1 (ja) 薬物含有粒子および該粒子を含む固形製剤
US20220071898A1 (en) Dipivefrin orally disintegrating tablet formulations
US20120276199A1 (en) Taste masked pharmaceutical formulations
US20110086070A1 (en) Orally disintegrating compositions of rhein or diacerein
WO2014127786A1 (fr) Composition pharmaceutique à désintégration orale comprenant de l'asénapine
WO2021240531A1 (fr) Formes posologiques transmucosales du remdésivir
EP2022497B1 (fr) Composition orale comprenant de l'acide 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-](3-hydroxy-1,2-benzisoxazol-6- yl)méthoxy]phényl]propionique ou un sel de celui-ci
US20060188565A1 (en) Rapidly bioavailable tablet and capsule formulations of diclofenac
US20110257159A1 (en) Orally disintegrating tablet formulations of mirtazapine and process for preparing the same
US20090269393A1 (en) Chewable Bilayer Tablet Formulation
KR100604034B1 (ko) 암로디핀 유리염기를 함유한 구강 속붕해정 및 그의 조성물
KR101111534B1 (ko) 구강 속붕해성 조성물 및 이의 제조방법
WO2022234593A1 (fr) Compositions sublinguales comprenant nintedanib ou un sel de celui-ci
US9717692B2 (en) Effervescent formulations comprising dexketoprofen
JP6061924B2 (ja) 口腔内分散性製剤
US8426461B2 (en) Orally dispersible tablet
US11020349B1 (en) Transmucosal dosage forms of remdesivir
KR101046789B1 (ko) 안정성이 개선된 암로디핀 속붕해성 정제 및 그의 제조방법
KR100503949B1 (ko) 염산 온단세트론의 쓴맛을 효과적으로 은폐한 경구용 구강속붕해정 조성물
JP2020196713A (ja) エドキサバンを含有する口腔内崩壊錠
ES2665868T3 (es) Comprimido que contiene material compuesto con ciclodextrina

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22798789

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22798789

Country of ref document: EP

Kind code of ref document: A1